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Abstract
To gain insight into regions of the platelet GPIIb-Ma com-
plex involved in receptor biogenesis and function, we exam-
ined the biochemical properties of a defective GPIIb-Ia
complex from patient suffering from type II Glanzmann
thrombasthenia. Flow cytometric as well as immunoblot
analysis of patient platelets showed significantly reduced
levels ofGPIIb and GPIa compared with a normal control.
Patient platelets, however, retained the ability to retract a
fibrin clot. Sequence analysis of PCR-amplified platelet
GPIIb mRNA revealed an Arg327-His amino acid substitu-
tion between the second and third calcium-binding domains
of the GPlIb heavy chain, a residue that is highly conserved
among integrin a-subunits. The recombinant His327 form of
GPIb was found to be fully capable of associating with
GPIa, therefore the role of the calcium-binding domains
in intersubunit association was further examined by con-
structing amino-terminal segments of GPIIb that ended be-
fore the first, second, and third calcium-binding domains.
All three fragments were found to associate with GPMa,
demonstrating that the calcium-binding domains of GPIIb
are not necessary for initial complex formation. Regions
amino-terminal to the calcium-binding domains of GPIEb
may play a heretofore unappreciated role in integrin subunit
association. (J. Clin. Invest. 1995. 95:1553-1560.) Key
words: integrins Glanzmann thrombasthenia * calcium-
binding domains protein trafficking - inherited platelet
defects
Introduction
In 1918, Glanzmann described a bleeding disorder that he
termed "thrombasthenie," meaning "weak platelets," mani-
fested by normal platelet counts but abnormal clot retraction
(1). Platelets from thrombasthenic patients could not spread
onto a glass surface (2) nor could they aggregate, indicating
that the platelets were functionally defective (3, 4). Glanzmann
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thrombasthenia (GT)' is now recognized as a rare autosomal
recessive platelet disorder that is clinically characterized by
lifelong mucocutaneous bleeding (5). This disease occurs in a
small fraction of the population; however, a high incidence
persists in confined geographical areas within certain ethnic
groups in which marriage is practiced among descendants of a
common ancestor (5). Thrombasthenic platelets fail to bind
fibrinogen and aggregate after stimulation by physiologic ago-
nists such as ADP, thrombin, epinephrine, or collagen (6).
GT has been subclassified based upon platelet intracellular
fibrinogen content and the ability of platelets to retract a fibrin
clot (7). Type I patients lack platelet fibrinogen and clot retrac-
tion, whereas type H thrombasthenic platelets contain apprecia-
ble levels of platelet fibrinogen and maintain some clot retrac-
tion capability. The basis of GT lies within an abnormality of
the genes that encode the major receptor for fibrinogen, glyco-
proteins (GP)IIb-Iia. GPIIb and 111a are specifically decreased
in thrombasthenic versus normal platelets (8). Type I GT pa-
tients lack detectable levels of GPHb-IHa, whereas type II GT
platelets express moderate (10-25%) levels of GPI1b-HIa (5).
Variant forms of thrombasthenia have also been described with
increasing frequency and are characterized as possessing normal
to near-normal levels of a dysfunctional form of GPIIb-HIa
present on the cell surface (9-12). Platelets from type I, type
H, and variant forms of GT are functionally indistinguishable
in that all fail to bind the adhesive ligand fibrinogen and self-
associate (aggregate) in response to platelet activation.
GPIIb-Ia (a0,83) is a member of the widely known recep-
tor family of integrins, which mediate the adhesion of cells to
each other and to the extracellular matrix (13). Glycoproteins
HIb (145,000 Mr) and lila (95,000 Mr) associate in a noncova-
lent, calcium-dependent manner to form a complex that is pres-
ent exclusively on platelets. The complex primarily mediates
the interaction of activated platelets with fibrinogen during he-
mostasis; however, GPIIb-hIa is also known to associate with
other adhesive ligands including von Willebrand factor, fibro-
nectin, and collagen (14, 15). Study of GPIIb-HIa complex
biosynthesis within cultured human leukemic and megakaryo-
cytic cell lines has led to a better understanding of key steps
that take place during the synthesis, assembly, and processing of
integrins (16-18). GPI~b and GPHIa subunits are synthesized
within the rough endoplasmic reticulum as single-chain mole-
cules and assembled into a pre-GPIIb-Iila complex. Oligosac-
charides, consisting mainly of high-mannose sugar moieties,
are added to both GPIIb and GPHIa within the endoplasmic
reticulum, representing 15 and 18% of each subunit's molec-
1. Abbreviations used in this paper: GT, Glanzmann thrombasthenia;
PRP, platelet-rich plasma.
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ular mass, respectively (19). Subsequent to complex assembly,
pre-GPIIb-IIIa is transported to the Golgi apparatus, where a
number of posttranslational modifications occur. Pre-GPIIb is
cleaved at amino acid 859 into a heavy (125,000 Mr) and light
(23,000 Mr) chain (20) that remains covalently linked by a
single disulfide bond formed by residues CYS826-CYS880 (21).
The high-mannose sugars of GPIIb are converted to complex
carbohydrates within the Golgi apparatus; however, most of the
sugar residues on GPIIIa remain of the high-mannose type.
After these processing events within the Golgi apparatus, the
mature GPIIb-IIIa complex is then rapidly transported to the
cell surface.
Analysis of molecular genetic defects present in GPIIb or
GPIIa of patients with GT has previously proved to be benefi-
cial toward defining precise structural domains of integrins that
play a role in the biosynthesis, subunit association, maturation,
expression, and function. Thus, two regions which play a role
in maturation of GPHIIb-Ia have been reported in GPIIb (22,
23), three separate mutations in GPIHa have helped to further
define regions involved in ligand binding and stability of the
GPIIb-IIIa complex (24-26), and a single amino acid substitu-
tion within the cytoplasmic domain of GPIIIa helped to define
a region involved in receptor activation (27). One of the pur-
poses of this investigation was to continue to identify such
regions by examining the molecular basis of naturally occurring
inherited defects that result in defective surface expression and
or function of integrin subunits. In this paper, we will demon-
strate that a single amino acid mutation between the second and
third calcium-binding domains of the integrin a subunit GPHb
slows intracellular trafficking to the cell surface, resulting in
type II GT. Characterization of the biosynthetic blockade in-
duced by this naturally occurring amino acid substitution has
revealed regions of GPIIb that appear to play important struc-
tural roles in the maturation and subunit association of integrin
complexes.
Methods
Patient studies. The propositus is a 14-yr-old German female, the prod-
uct of a consanguineous marriage, who presented with severe hemor-
rhage after a tonsillectomy. The patient has a history of frequent bruising
and bleeding after the shedding of her deciduous teeth. Although the
patient had a normal platelet count, she had a prolonged cutaneous
bleeding time > 20 min. Subsequent studies revealed absent ex vivo
platelet aggregation in response to ADP, collagen, epinephrine, and
arachidonic acid, but normal platelet aggregation in response to risto-
cetin, consistent with a diagnosis of GT. Blood samples for the studies
described below were obtained from the patient, her mother, other family
members, and normal volunteers after informed consent.
Clot retraction. Whole blood was anticoagulated with ACD-A and
centrifuged at 200 g for 10 min at room temperature to produce platelet-
rich plasma (PRP). After centrifugation, only the upper two-thirds of
the PRP (to reduce white cell contamination) were transferred to a
second polypropylene tube. Platelets were diluted with platelet poor
plasma to final concentrations of 2.5, 1.25, and 0.675 x 108 platelets/
ml. Platelet suspensions were incubated for 5 min at 370C, then 4 ,ul of
1 M CaCl2 was added to each tube. A clot was allowed to form and
contract over 1 h at room temperature. Clot formation and retraction
capability of platelets from a normal control were compared with plate-
lets from the patient (KJ) and a previously reported type I Glanzmann
thrombasthenic (KW) (28).
Antibodies. The monoclonal antibody Tab, specific for GPIIb (29)
was a generous gift from Dr. Rodger McEver (University of Oklahoma).
The monoclonal antibody AP3, specific for GPIIIa, has been described
(30). The monoclonal antibody AP2, which recognizes an epitope on
the GPIIb-IIIa complex (31), and the monoclonal antibody APl, which
recognizes an epitope on GPIb, was kindly provided by Dr. Robert R.
Montgomery (Blood Research Institute, The Blood Center of Southeast-
ern Wisconsin, Milwaukee, WI).
Flow cytometric analysis of platelet membrane glycoproteins.
Whole blood from thrombasthenic patients and normal controls was
anticoagulated with ACD-A, and platelets were prepared by differential
centrifugation using standard techniques. For the assay, 5 x 106 platelets
were aliquoted into polypropylene tubes and then incubated with fluo-
rescein isothiocyanate-conjugated anti-GPIb antibody (API) (21 pg/
ml), anti-GPIIIa antibody (AP3) (26 pg/ml), anti-GPIb antibody
(Tab) (32 pg/ml), anti-GPIIb/IIIa antibody (AP2) (26 ig/ml) for 1
h at room temperature in the dark. Samples were analyzed on a FACStar
Plus® flow cytometer (Becton Dickinson Mountain View, CA) as pre-
viously described (32), and data were analyzed using Becton Dickinson
Lysys software.
Platelet membrane glycoprotein analysis. Detergent platelet lysates
from both normal and thrombasthenic individuals were prepared as
previously described (33), added to the wells of a 5-15% gradient
SDS-polyacrylamide gel, and electrophoresed under reducing condi-
tions. Platelet proteins were transferred to an Immobilon-P membrane
(Millipore Corp., Bedford, MA), which was then incubated with rabbit
polyclonal antiserum directed against GPIIb (5 pg/ml) or GPIHa (20
pg/ml). Bound antibodies were detected by incubation of the mem-
brane with goat anti-rabbit IgG conjugated to alkaline phosphatase and
visualized by development with the nitro blue tetrazolium/5-bromo4-
chloro-3-indolyl phosphate substrate pair (Sigma Immunochemical, St.
Louis, MO).
Amplification of platelet messenger mRNA. Platelet messenger
mRNA was isolated from 50 ml of whole blood and reverse transcribed
into cDNA with a GPIlb-specific antisense oligonucleotide primer and
Moloney murine leukemia virus reverse transcriptase (Life Technolog-
ies, Inc., Gaithersburg, MD) using previously described methods (32).
Overlapping PCR products were directly cloned into pGEM-Szf(+)
vector (Promega Corp., Madison, WI) before nucleotide sequence anal-
ysis using the Sequenase kit (United States Biochemical Corp., Cleve-
land, OH).
Site-directed mutagenesis of GPIIb cDNA. The full length cDNA
encoding wild-type GPIIb (generous gift of Dr. Morty Poncz, Children's
Hospital of Philadelphia, Philadelphia, PA) was cloned into plasmid
vector pGEM-7zf(+) (Promega Corp.). The transformer site-directed
mutagenesis kit (Clontech, Palo Alto, CA) along with two single-nucle-
otide mismatched primers was used to construct a GPIIb cDNA which
encoded a mutated form of GPIIb. A single-nucleotide mismatched
primer (5'-GAAGTGGGGCATGTGTATTTG-3') which abolishes a
unique restriction site (XbaI) on pGEM-7zf(+) was used to allow
positive selection of mutated clones. Single-nucleotide mismatched
primer (5'-GAAGTGGGGCATGTGTATTTG-3') from base 1064 to
1084 of GPHb was used to construct a mutant form of GPHb. This
construct containing a nucleotide substitution, as well as the wild-type
GPIIb cDNA, was treated with the unique restriction enzymes BsmI and
AccI (New England Biolabs, Beverly, MA). The restriction-digested
mutated cartridge was exchanged for the wild-type sequence to construct
the cDNA which encodes the mutated form of GPIIb found in patient
KJ. The cDNA was excised from pGEM-7zf( +) with EcoRI and ligated
into the mammalian expression vector EMC3 (gift of Dr. Glenn Larsen,
Genetics Institute, Boston, MA). cDNAs were subjected to nucleotide
sequence analysis to confirm the presence of the mutation and proper
insertion of the cartridge into the wild-type GPIIb cDNA.
Synthesis ofGPIIb amino-terminalfragments. Three amino-terminal
fragments of GPIIb were amplified by PCR with a template of full length
GPIIb cDNA within plasmid vector pGEM-7zf(+). The previously
mentioned primer (5'-GAAGTGGGGCATGTGTATTTG-3') which
binds to the multiple cloning region of pGEM-7zf(+) served as the
5' sense primer for each PCR fragment. The antisense primer (5'-
CTAGAATTCTCATAACTCGCCCACGGCCACCGAGTA-3') from
nucleotides 823 to 803 served as the 3' primer for a fragment which
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encoded amino acids 1-243 of GPIIb in addition to encoding three stop
sequences and an EcoRI site. The antisense primer (5 '-CTAGAATTC-
TCATAAAGTGACAGCCACTGAATGCCC-3') from nucleotides 983
to 963 served as the 3' primer for a fragment which encoded amino
acids 1-296 of GPIlb in addition to encoding three stop sequences and
an EcoRI site. The antisense primer (5 '-CTAGAATTCTCATAAGCC-
CAGGGGTGCGATGGCAGA-3') from nucleotides 1186 to 1166
served as the 3' primer for a fragment which encoded amino acids1-
364 of GPIIb in addition to encoding three stop sequences and an EcoRI
site. Three nucleotide strands which encode GPHb fragments were syn-
thesized by PCR using Vent Polymerase (New England Biolabs) and
treated with EcoRI (New England Biolabs) producing EcoRI sticky
ends. The PCR products were then isolated with Gene Clean H kit
(Bio 101, La Jolla, CA) and ligated into mammalian expression vector
pcDNA3 (Invitrogen, San Diego, CA) at its EcoRI site. Single clones
that encoded GPIlb fragments were treated with restriction enzymes to
verify the correct insert size and orientation. Constructs were transfected
into Cos-7 cells and analyzed as described below.
Immunoprecipitation analysis of GPI~b-IIIa transfected COS cells.
Cos-7 cells were transfected with GPI1b and GPIIIa expression con-
structs as previously described (23), cultured for 48-72 h, and then
metabolically labeled with [35S]methionine (600pCi/plate) (NEN-
DuPont, Boston, MA). Detergent lysates were prepared, precleared with
protein A-Sepharose (Sigma Immunochemicals) and incubated with
10 ,g of monoclonal or 25 Mg of polyclonal antibody for 18 h at 40C
with mixing as described (23). 5 Mg of goat anti-mouse IgG was added
to samples containing monoclonal antibodies of the IgG, subclass and
incubated for an additional hour at room temperature. Beads were
washed, placed in 50 Ml of 2x reducing buffer (4% sodium dodecyl
sulfate, 10% /3-mercaptoethanol, 100 mM Tris-HCl, pH 6.8, 10% glyc-
erol, and 0.001% bromophenol blue), boiled for 10 min, centrifuged,
and the supernatants electrophoresed overnight on a 7% SDS-PAGE
gel. Gels were fixed in 45% methanol, 12% acetic acid for 30 min,
incubated in Enlightening (DuPont) for 30 min, dried, and exposed to
Kodak XRP film for 8-20 h at -80°C.
Biotin labeling and detection of cell surface proteins. Transfected
Cos-7 cells were biotin-surface labeled as described previously (23).
After biotinylation, cells were solubilized in Triton X-100 and immuno-
precipitated as described above. Immunoprecipitates were subjected to
SDS-PAGE and transferred onto Immobilon membranes (Millipore
Corp.), which were then incubated in a 1:4,000 dilution of streptavidin-
horseradish peroxidase (Amersham, Arlington Heights, IL) for 1 h at
room temperature. After washing, blots were incubated in detection
reagents 1 and 2 (ECG kit; Amersham) for 1 min and exposed to
Hyperfilm (Amersham) for up to 3 min.
Results
GPIb-IIa content andfunction ofpatient KJ's platelets. Plate-
lets from Glanzmann thrombasthenic patient KJ were examined
by flow cytometry for the expression of GPIIb-IIIa (see Meth-
ods). Platelets were isolated and incubated with FITC-conju-
gated antibodies specific for GPIb (AP-1), GPIIIa (AP3),
GPHb (Tab), or the GPIIb-IIIa complex (AP2) (Fig. 1). Plate-
lets from all individuals examined expressed similar levels of
GPIb (Fig. 1, A and B. upper left); however, antibodies specific
for GPIIb, GPIIIa, and the GPILb-Hla complex demonstrated
that patient KJ expressed only 7-10% of the normal content
of GPIIb-IIIa on the platelet surface. Her platelet GPIIb-IIIa
surface expression was higher than that of type I GT patient
KW (Fig. 1 A), while her mother, EJ, expressed 55% GPHb-
II1a, consistent with her status as a carrier of thrombasthenia
(Fig. 1 B). Based upon these observations, we provisionally
classified KJ as a type II thrombasthenic.
To confirm the type H Glanzmann phenotype, KJ's platelets
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Figure 1. Flow cytometric analysis of platelet membrane glycoproteins.
Platelets from Glanzmann thrombasthenic patients KJ and KW, KJ's
mother (EJ), and a normal control were resuspended in Ringer's citrate
dextrose buffer, pH 6.5, at 5 x 106 platelets per ml, and then incubated
with FITC-labeled anti-GPIb antibody (API), anti-GPIIfa antibody
(AP3), anti-GPIIb antibody (Tab), or anti-GPIIb/HIa antibody (AP2)
as described in Methods. Samples were analyzed on a FACStar Plus®
flow cytometer, and the data were analyzed with Becton Dickinson
Lysys software. Fluorescence intensities were converted to arbitrary
linear units shown above each histogram. A compares the relative level
of platelet surface protein from a normal control, type I Glanzmann
thrombasthenic patient KW, and type H Glanzmann thrombasthenic
patient KJ. B compares the relative level of platelet surface protein from
a normal control, patient KJ, and KJ's mother, EJ, an obligate carrier
for thrombasthenia.
Platelets were isolated, serially diluted with platelet poor
plasma, and treated with calcium chloride at room temperature
for 1 h (see Methods). As shown in Fig. 2, platelets from type
I patient KW (28) lacked the ability to retract a fibrin clot (Fig.
2, right) compared with the normal control, which retracts the
fibrin clot appreciably (Fig. 2, left). Platelets from patient KJ
were found to maintain some clot retraction capability (Fig. 2,
middle). These data support KJ's classification as a type II
Glanzmann thrombasthenic patient resulting from a defective
GPIIb or GPHIa subunit.
To investigate the molecular basis for thrombasthenia in
this patient, KJ's platelets were next examined for total GPIIb-
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Ila content. Immunoblot analysis (Fig. 3) demonstrated that
the patient's mother's (EJ) platelet lysates contained 50%
levels of glycoprotein IIb, while platelets from KJ contained
little detectable GPIIb. In contrast the patient (KJ) did express
a small amount of GPIIIa at increasing concentrations of platelet
protein, presumably as part of the vitronectin receptor (a!133)
complex. Based upon these data, we examined the nucleotide
sequence of the GPIIb mRNA transcript from this patient for a
molecular genetic defect.
Analysis of (KJ) GPIIb mRNA. Platelet messenger RNA
was isolated and reverse transcribed into cDNA using a GPIIb-
specific antisense nucleotide primer (see Methods). Four over-
lapping fragments which spanned the entire length of GPIIb
cDNA were amplified by PCR. Secondary PCR products were




Figure 2. Clot retraction of types I and II
thrombasthenic platelets. Whole blood from
type I GT patient KW, type II GT patient KJ,
and a normal control were anticoagulated
with ACD-A and centrifuged at 200 g for 10
min at room temperature to produce PRP.
For sample (U), platelets were diluted with
platelet poor plasma to a final concentration
of 2.5 x 108 platelets/ml. Platelets were fur-
ther diluted to one-half and one-fourth this
concentration as indicated to make the assay
semiquantitative. Clots were photographed 1
h after addition of CaCl2. Note that whereas
type I GT platelets failed to retract the fibrin
clot, KJ's platelets were 50% effective.
synthesized using nested primers, producing a total of 10 frag-
ments of GPIIb cDNA. Examination of the nucleotide sequences
of these GPI~b PCR products revealed a single G,074-+A nucleo-
tide substitution in KJ's GPIIb cDNA (Fig. 4). This results in
the transformation of Arg327 to His in the GPIIb polypeptide
chain. Alignment of this region of GPIIb with all other known
integrin a-subunits from Drosophila to humans revealed the
presence of an arginine or glutamine at this relative position
between the second and third cation binding domains of integrin
a-subunits (Table I). The substitution of histidine conserves a
positive charge at this position, however an additional stearic
constraint is placed upon the GPilb subunit which may have
an effect on the processing or ligand binding capability of the
GPIIb-Iila complex.
Effect of Arg327-+His substitution on biogenesis of the
GPIIb-IIIa complex. To determine whether the Arg327-4His mu-
tation of GPIIb represents a neutral polymorphism, or an altered
structural region which is responsible for the reduced level of
GPilb-IHIa on the platelet surface in patient KJ, an expression
vector encoding the His327 form of GPIIb was constructed (see
Methods) and cotransfected with a vector encoding wild-type
GPIia into Cos-7 cells. Transfected Cos-7 cells were surface
labeled with biotin 72 h after transfection and then subjected to
immunoprecipitation analysis using antibodies directed against
glycoproteins IIb and mia. As shown in Fig. 5, the His327 GPIIb-
HIla complex was detectable on the cell surface, but at greatly
reduced levels relative to the wild-type Arg327 GPIIb-Iia com-
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Figure 3. Semiquantitative immunoblot analysis of platelet GPIIb-Illa
content. Detergent lysates of whole platelets were prepared from a nor-
mal control, the patient's mother (EJ), and the patient (KJ). 25-250
jsg total protein was loaded onto a 5-15% PAGE gel and electropho-
resed under reducing conditions. After transfer to Immobilon mem-
branes, the blot was incubated with a mixture of rabbit polyclonal anti-
bodies specific for GPI~b (5 jig/ml) and GPIIIa (20 jig/ml). Immunore-
active bands were detected as described in Methods. The band at 190,000
Mr is thought to represent GPIila dimer and is most prominent in the
patient lysate. From these data, patient KJ appears to express 10-
15% of GPIIIa, while his mother's platelets contain 50-60% levels.
The absence of GPIIb after detergent solubilization differs from the
results seen by flow cytometric analysis of intact platelets (Fig. 1) and
is likely due to an instability in the GPIIb subunit induced by a mutation.
Molecular mass markers are to the right in kilodaltons.
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Figure 4. Nucleotide sequence analysis of KJ versus normal GPIIb.
Platelet mRNA PCR was used to amplify overlapping segments of the
GPHb mRNA transcript, and the resulting cDNA fragments were sub-
jected to DNA sequence analysis. Nucleotides 1070-1079 of GPIIb,
which encode amino acids 326-328, are shown and illustrate the single
GC-A point mutation that results from substitution of a His for Arg327.
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Table I. Comparison of alb Amino Acid Sequence to Other
Integrin a-Subunits
,3-Subunit a-Subunit a-Subunit amino acid sequence
a2 EEG R VYLF
a4 EEG R VFVY
a5 EVG R VYVY
Drosophila ap2 DVG R VYIL
/32 aL RGG R VFIY
aM RGG Q VSVC
ax RGG Q VSVC
/33 av EVG Q VSVS
Rodent aIlb EVG R VYLF
Human am EVG R VYLF
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plex. These data demonstrate that this single amino acid substi-
tution in GPHb is sufficient to reduce surface expression of
GPIlb-IHa, consistent with the type II Glanzmann phenotype.
To examine the effects of this mutation on the ability of
GPIIb and GPIIIa to form a heterodimer complex, both wild-
type and mutant forms of GPIIb cDNA were cotransfected with
GPHIa cDNA, pulsed with [35S ] methionine for 9 h, and immu-













Figure 5. Immunoprecipitation analysis of biotin surface-labeled
transfected Cos-7 cells. Cos-7 cells were transfected with the indicated
expression plasmid constructs and after a 72-h incubation period were
surface labeled with NHS-biotin. Immunoprecipitation using the sub-
unit-specific antibodies, Tab or AP3, revealed that substitution of a
single histidine residue for the wild-type arginine at amino acid 327 of
GPIIb resulted in a decreased level of surface-expressed GPIIb-Illa,
consistent with the thrombasthenic phenotype of the patient's platelets.
Identical results were obtained using polyclonal anti-GPIIb or GPIIa
antibodies (not shown). Molecular mass markers are to the left in
kilodaltons. The band at 95 kD immunoprecipitated by AP3 in the
GPIIIa transfection likely represents recombinant GPIIa that became
surface expressed as a result of its complexing with endogenous Cos
cell vitronectin receptor a-subunit, as previously observed by others
(43).
Figure 6. Maturation of wild-type versus His327 GPIlb-IIIa complexes.
Cos-7 cells were cotransfected with cDNA encoding GPIIa and either
the Arg327 (wild-type) or His327 (mutant) form of GPIIb. After a 9-h
pulse with [35S]methionine, total cellular lysates were prepared, and
subunit association was assessed by immunoprecipitation with the anti-
GPIIIa-specific monoclonal antibody, AP3. Immunoprecipitates were
analyzed by fluorography of a 7% acrylamide gel under reducing condi-
tions. Coprecipitation of either pro-GPIIb or mature GPI1b indicates that
complex formation has taken place. Note the ability of the His327 form
of pro-GPI~b to complex with GPIIIa, but its failure to traffic efficiently
to the Golgi apparatus and become cleaved into heavy and light chains.
Mock denotes vector without insert as a negative control. Molecular
mass markers are to the left in kilodaltons.
AP3. As shown in Fig. 6, both the precursor and mature forms
of wild-type Arg327 GPIIb coprecipitated, confirming their asso-
ciation with GPIIa. The presence of mature Arg327 GPIIb in
the immunoprecipitate is indicative that some of the complex
had proceeded to the Golgi apparatus, where cleavage of pro-
GPIIb into heavy and light chains has taken place. The His327
form of pro-GPIIb also associated with GPIIIa, as evidenced
by the coimmunoprecipitation of both subunits by AP3, but the
immunoprecipitates contained reduced to nondetectable levels
of the mature His327 GPHb heavy chain, demonstrating that the
Arg327-+His mutation of GPIIb inhibited the kinetics of pro-
cessing of this receptor as it traffics to the cell surface.
Role ofthe calcium-binding domains in GPIIb-lla associ-
ation. Patient KJ represents the third Glanzmann patient to be
characterized as having a missense mutation within or immedi-
ately proximal to one of the calcium-binding domains of GPIIb
(22, 23). Interestingly, despite the importance ascribed to cal-
cium ions in supporting the formation and integrity of the
GPIhb-Ia complex (34-37), subunit association appears to
be unaffected by mutations in either the first (22), second/third
(this paper), or fourth calcium-binding domains of GPIlb (23).
To further examine the role of the GPIIb calcium-binding do-
mains in subunit association, we constructed recombinant GPIIb
fragments that contained the signal peptide and amino terminus,
but ended before the first (residues 1-243), second (residues
1-296), or third (residues 1-364) calcium-binding domains.
After cotransfection with full length GPIIIa into Cos-7 cells,
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Figure 7. Role of GPIIb calcium-binding domains in the association of
GPIIb with GPIIa. Eukaryotic expression vectors encoding GPIIb frag-
ments ending before the first (amino acids 1-243), second (residues
1-296), and third (residues 1-364) calcium-binding domains were
constructed and cotransfected with a vector encoding full length GPIIIa
into Cos-7 cells. Newly synthesized proteins were metabolically labeled
with [35S]methionine, immunoprecipitated with a polyclonal antibody
directed against GPIIb, and analyzed by SDS-PAGE and autoradiogra-
phy under reducing conditions. Coprecipitation of GPHIa by the GPIIb-
specific polyclonal antibody indicates that association between GPIIb
and GPHIa has taken place. Vector without insert (Mock), GPIIa
transfected alone, and full length GP1Ib transfected alone served as
controls for antibody specificity. Note that GPIIa was coprecipitated
with each fragment of GPIIb (1-243, 1-296, 1-364). Fragments 1-
243, 1-296, and 1-364 contain 0, 1, and 2 methionines, respectively,
which are available to metabolic label; therefore the GPIIb fragments
are detected at different intensities. Coprecipitation of the GPIIb frag-
ments was also found using antibodies directed against GPIIIa (not
shown). Molecular mass markers are to the left in kilodaltons.-
newly synthesized proteins were metabolically labeled with
[31S]methionine for 9 h and immunoprecipitated with a poly-
clonal antibody directed against GPIIb. As shown in Fig. 7,
when full length GPIIb was cotransfected with GPIIIa, both
proteins were immunoprecipitated by the GPIlb-specific anti-
body, indicating that subunit association between GPIIb and
GPIia had taken place. Somewhat unexpectedly, GPIHa was
also coprecipitated with each of the truncated fragments of
GPIIb, including the one that ended before the first calcium-
binding domain. Fragments 1-243, 1-296, and 1-364 contain
0, 1, and 2 methionines, respectively, that are available to meta-
bolic label; therefore, the GPI~b fragments are detected at differ-
ent intensities. Nonetheless, nearly equal amounts of GPIIla
were immunoprecipitated in each instance, indicating that each
GPHb fragment quantitatively associated with GPIIIa. These
data indicate that calcium-binding domains may not be neces-
sary for initial subunit association of GPIIb with GPIIIa and
may in part explain our observations that a single amino muta-
tion between the second and third calcium-binding domains did
not affect formation of the pro-GPilb-GPHIa complex.
Discussion
We report the first characterization of a molecular genetic defect
resulting in type II GT. Classification as type II GT was a
result of detecting > 5% GPIlb-iHIa on KJ's platelets by flow
cytometry (Fig. 1) and due to the ability of KJ's platelets to
partially retract a fibrin clot (Fig. 2). Western blot analysis of
KJ's platelet protein revealed a substantial reduction in the level
of GPIIb and GPIila (Fig. 3), with GPIila present in slightly
greater amounts, presumably due to its additional association
with the vitronectin receptor a-subunit (avf33). Based upon
these results, we examined the nucleotide sequence of the
mRNA transcript encoding GPilb and found a single G1074A
nucleotide substitution that resulted in an Arg327-.His amino
acid substitution (Fig. 4) between the second and third calcium-
binding domains of GPIIb. The conformational constraints
placed upon this region of GPIlb by this mutation conceivably
could have multiple effects on receptor function in terms of
subunit stability, calcium-mediated subunit association, or li-
gand binding ability. Interestingly, residue 327 is positioned
only 13 amino acids away from the region on GPIIb shown to
interact with the y-chain dodecapeptide of fibrinogen (38).
Moreover, the presence of an arginine at this location is highly
conserved among other integrin a-subunits (Table I), sug-
gesting an important role for this residue in integrin structure
or function.
We determined that the Arg327-His amino acid substitution
in GPHb was not a naturally occurring neutral polymorphism
of GPHb, but instead was the defect that resulted in GT in
patient KJ. Mammalian expression vectors encoding GPiHIa and
the His327 form ofGPHb were constructed and cotransfected into
Cos-7 cells. Biotin-labeling of cell surface proteins followed by
immunoprecipitation analysis demonstrated that substitution of
a single histidine residue resulted in a highly reduced level of
GPlb-Iila on the Cos-7 cell surface (Fig. 5), consistent with
the thrombasthenic phenotype resulting in defective platelet ag-
gregation.
Recently, two other thrombasthenic patients have been de-
scribed that harbor single amino acid substitutions within cal-
cium-binding domains of GPI~h. Interestingly, both mutations
(Gly273-+Asp within the first calcium-binding domain [22], and
Gly418-+Asp flanking the fourth calcium-binding domain [23])
introduced an additional negatively charged residue proximal
to aspartate residues within a calcium-binding domain, and in
each case resulted in the complete absence of GPIIb-Ia from
the cell surface, i.e., type I GT. In contrast, the Arg327-+His
mutation in type II GT patient KJ preserved an existing positive
charge and resulted in only a partial biosynthetic blockade in the
maturation of the integrin GPIhb-Iila complex. Ligand binding
functions of the residual complex that reaches the cell surface
appear to be relatively unaffected by the nature of this mutation,
as evidenced by the ability of KJ's platelets to retract a fibrin
clot, which is preceded by fibrin interactions with GPHb-IHa
(39). Residual av43 does not appear to be capable of mediating
clot retraction, since platelets from type I patient KW, who also
has a normal complement of aYv33, failed to retract a fibrin clot
(Fig. 2).
It has been recognized for more than 10 yr that the GPI~b-
IIa complex requires the presence of calcium to maintain sub-
unit association (34-37), and it has recently been shown that
optimal fibrinogen binding occurs when each of the four cal-
cium-binding sites are occupied (40). The precise relationship,
if any, between the role of calcium in maintaining subunit asso-
ciation versus its role in mediating ligand binding to the com-
plex is as yet unclear. The opportunity to analyze the effects of
the three unique mutations described above that result in GT,
each proximal to one of the calcium-binding domains of GPIIb,
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has enabled us to begin to make some observations regarding
the role of these domains in integrin biogenesis and function.
In each case, substitution for a highly conserved amino acid
within or proximal to a calcium-binding domain did not affect
association of pro-GPIIb with GPHIa, though downstream ef-
fects on maturation of the GPIIb-IHa complex ultimately led
to the thrombasthenic phenotype. These data suggest that a
region(s) outside the calcium-binding domain may participate,
at least early on, in subunit association. Interestingly Rosa and
McEver (18) have already shown that the pro-GPIIb-Ila com-
plex is less easily dissociable by EDTA treatment than is mature
GPIIb-llIa, supporting the notion that the association of pro-
GPIIb with GPIIa that occurs during early biogenesis may be
calcium independent.
To test this hypothesis, we constructed three overlapping
amino terminal fragments of GPIIb containing none, one, or
two calcium-binding domains and examined their interaction
and association with GPHIa. All three fragments, including one
that contained no calcium-binding domains (residues 1-243),
were able to associate with GPIIa (Fig. 7). These data demon-
strate that the calcium-binding domains of GPIIb are not neces-
sary for initial association of GPIIb with GPIIIa and provide a
possible explanation for the observation that amino acid substi-
tutions at or near calcium-binding domains of GPIIb do not
affect formation of the pro-GPIIb-GPHIa complex.
Several other investigators have examined the structural re-
quirements for integrin subunit association. Lam et al. (41)
used mild reduction to dissociate the heavy chain of GPIIb
from the light chain and showed that the heavy chain was still
complexed with GPIHa. Calvete and colleagues (42) used lim-
ited proteolysis of isolated heterodimers followed by protein-
chemical analysis of the resulting peptide fragments to identify
a number of putative contact sites between GPIIb and GPIIa.
Interestingly, these authors were able to deduce that three re-
gions of the GPIIb heavy chain were involved in intersubunit
interactions: amino acids 486-553, 696-734, and 780-814.
They also proposed that residues 901-946, located within the
GPIIb light chain, formed a contact site with GPLIa. They found
no evidence that the amino terminus of GPIIb interacted with
GPIHa, however, most probably due to the fact that this region
is highly susceptible to proteolytic degradation, and is therefore
not amenable to analysis using their approach. Finally, Wippler
et al. (43) constructed and expressed in baculovirus truncated
subunits consisting of GPHb 1-874 and GPIIa 1-469 and
showed that these residues were sufficient to form a heterodimer
complex and bind ligand. Our studies further showing that sub-
unit association may require only residues 1-243 help to further
define the domains involved in noncovalent intersubunit interac-
tions and provide an additional example of the unique contribu-
tions that can be provided through detailed examination of the
biochemical consequences of naturally occurring inherited
platelet defects.
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